Author:
Elter Adrian,Bock Tina,Spiehl Dieter,Russo Giulio,Hinz Steffen C.,Bitsch Sebastian,Baum Eva,Langhans Markus,Meckel Tobias,Dörsam Edgar,Kolmar Harald,Schwall Gerhard
Abstract
AbstractSince the pandemic outbreak of Covid-19 in December 2019, several lateral flow assay (LFA) devices were developed to enable the constant monitoring of regional and global infection processes. Additionally, innumerable lateral flow test devices are frequently used for determination of different clinical parameters, food safety, and environmental factors. Since common LFAs rely on non-biodegradable nitrocellulose membranes, we focused on their replacement by cellulose-composed, biodegradable papers. We report the development of cellulose paper-based lateral flow immunoassays using a carbohydrate-binding module-fused to detection antibodies. Studies regarding the protein binding capacity and potential protein wash-off effects on cellulose paper demonstrated a 2.7-fold protein binding capacity of CBM-fused antibody fragments compared to the sole antibody fragment. Furthermore, this strategy improved the spatial retention of CBM-fused detection antibodies to the test area, which resulted in an enhanced sensitivity and improved overall LFA-performance compared to the naked detection antibody. CBM-assisted antibodies were validated by implementation into two model lateral flow test devices (pregnancy detection and the detection of SARS-CoV-2 specific antibodies). The CBM-assisted pregnancy LFA demonstrated sensitive detection of human gonadotropin (hCG) in synthetic urine and the CBM-assisted Covid-19 antibody LFA was able to detect SARS-CoV-2 specific antibodies present in serum. Our findings pave the way to the more frequent use of cellulose-based papers instead of nitrocellulose in LFA devices and thus potentially improve the sustainability in the field of POC diagnostics.
Funder
Merck Lab @ Technical University of Darmstadt
Deutsche Forschungsgemeinschaft
Technische Universität Darmstadt
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. St John, A. The evidence to support point-of-care testing. Clin. Biochem. Rev. 31, 111–119 (2010).
2. Choi, J. R., Yong, K. W., Choi, J. Y. & Cowie, A. C. Emerging point-of-care technologies for food safety analysis. Sensors (Basel) 19, 817 (2019).
3. Abel, G. Current status and future prospects of point-of-care testing around the globe. Expert Rev. Mol. Diagn. 15, 853–855. https://doi.org/10.1586/14737159.2015.1060126 (2015).
4. FDA Authorizes First Point-of-Care Antibody Test for COVID-19 (2020).
5. marketsandmarkets. Point of Care Diagnostics Market, https://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html (2019).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献